Search / Trial NCT06232616

Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema

Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Jan 28, 2024

Trial Information

Current as of December 21, 2024

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • symptomatic patients aged 40 years or above with idiopathic stage 3-4 epiretinal membrane defined on the basis of spectral-domain optical coherence tomography classification;
  • central retinal thickness \>300 µm;
  • cystoid oedema within a 1 mm diameter range with the macular fovea as the center;
  • ocular axial length less than 25.00 mm.
  • Exclusion Criteria:
  • concomitant or previous macular diseases that may hinder visual improvement other than epiretinal membrane (e.g., age-associated macular degeneration, retinal vein occlusion, or diabetic macular oedema);
  • previous vitreoretinal surgery or intravitreal injection history;
  • history of glaucoma or optic neuropathy of any kind;
  • patients with uncontrolled systemic diseases or infectious diseases;
  • patients who took medicines that may have ocular side effects, such as glucocorticoid or hydroxychloroquine.

Trial Officials

Tao Sun, Ph.D.

Study Chair

Shanghai Eye Diseases Prevention & Treatment Center

About Shanghai Eye Disease Prevention And Treatment Center

The Shanghai Eye Disease Prevention and Treatment Center is a leading clinical research organization dedicated to advancing the understanding and treatment of ocular diseases. With a strong emphasis on innovation and patient-centered care, the center collaborates with various stakeholders, including academic institutions and healthcare providers, to conduct rigorous clinical trials. Its mission is to enhance eye health outcomes through evidence-based research, contributing to the global body of knowledge in ophthalmology. The center is committed to fostering a culture of excellence in clinical practices, ensuring the highest standards of safety and efficacy in all its research endeavors.

Locations

Shanghai, Shanghai, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0